Auristatin E-d8

• Description:

  Auristatin E-d8 is the deuterium labeled Auristatin E (HY-15582) . Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC) . Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids[1][2][3].

• UNSPSC:

  12352211

• Target:

  ADC Payload; Isotope-Labeled Compounds; Microtubule/Tubulin

• Related Pathways:

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton; Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Purity:

  99.48

• Smiles:

  CC(C)[C@H](N(C)C)C(NC(C(N([C@@H]([C@@H](C)CC)[C@@H](CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(N[C@H](C)[C@H](C2=CC=CC=C2)O)=O)=O)OC)C)=O)([2H])C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O

• Molecular Formula:

  C40H61D8N5O7

• Molecular Weight:

  740.05

• References & Citations:

  [1]MADDON Paul J, et al. PSMA ANTIBODIES AND PROTEIN MULTIMER. 2002 October 23. WO 03/034903 A2|[2]Peter D. Senter, et al. PENTAPEPTIDE COMPOUNDS AND USES RELATED THERETO. 2005 Jan. 13. US 2005/0009751 A l.|[3]LAW, Che-Leung, et al. TREATMENT OF IMMUNOLOGICAL DISORDERS 5 USING ANTI-CD30 ANTIBODIES. 2002 November 20. WO 03/043583 A2.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, protect from light, stored under nitrogen)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported